Scarica l'app Stockscreener
43.21
3.60%
1.50
Precedente Chiudi:
$41.71
Aprire:
$41.56
Volume 24 ore:
119.10K
Relative Volume:
0.99
Capitalizzazione di mercato:
$477.72M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+15.17%
1M Prestazione:
+63.30%
6M Prestazione:
+155.98%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$40.92
$44.04
Intervallo di 1 settimana:
$37.33
$44.04
Portata 52W:
$11.17
$44.04
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Nome
Palvella Therapeutics Inc
Settore
Industria
Telefono
(484) 253-1461
Indirizzo
125 STRAFFORD AVE, WAYNE
Confronta PVLA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
43.21 | 461.13M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-06 | Iniziato | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-04-09 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-26 | Iniziato | Stifel | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-20 | Iniziato | Canaccord Genuity | Buy |
| 2025-02-05 | Iniziato | TD Cowen | Buy |
| 2024-12-26 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Iniziato | Robert W. Baird | Outperform |
| 2018-03-19 | Iniziato | Evercore ISI | Outperform |
| 2018-03-19 | Iniziato | Jefferies | Buy |
| 2018-01-16 | Reiterato | H.C. Wainwright | Buy |
| 2017-05-30 | Iniziato | Rodman & Renshaw | Buy |
| 2016-08-05 | Ripresa | ROTH Capital | Buy |
| 2015-08-12 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-07-27 | Iniziato | Oppenheimer | Outperform |
| 2015-07-22 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Palvella Therapeutics Inc Borsa (PVLA) Ultime notizie
Is Palvella Therapeutics Inc. stock entering bullish territorySecure Buy Strategy Based on Risk Parameters - Newser
Is Palvella Therapeutics Inc. forming a reversal patternSwing Candidate List with Trade Cues - Newser
How hedge fund analytics apply to Palvella Therapeutics Inc. stockFree Stock Selection With High Accuracy - Newser
Palvella Therapeutics CEO to Speak at Canaccord Genuity Growth Conference - MSN
Risk vs reward if holding onto Palvella Therapeutics Inc.Portfolio Risk Distribution Analysis Tool - Newser
Palvella Therapeutics (PVLA) to Release Earnings on Thursday - Defense World
Will Palvella Therapeutics Inc. stock recover after recent dropFree Trend Analysis for Safer Trades - Newser
Detecting price anomalies in Palvella Therapeutics Inc. with AIFree Daily Chart Pattern Stock Forecast - Newser
What indicators show strength in Palvella Therapeutics Inc.AI Powered Stock Market Trend Forecast - Newser
What institutional flow reveals about Palvella Therapeutics Inc.Weekly Growth Portfolio Performance Summary - Newser
Palvella Therapeutics to Report Q2 Financials and Corporate Update on August 14 - MSN
Will Palvella Therapeutics Inc. price bounce be sustainableInvestment Life Cycle Planning Summary - Newser
How Palvella Therapeutics Inc. stock performs during market volatilityAsset Allocation Summary With Future Outlook - Newser
Will Palvella Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsBreakout Monitoring with Momentum Analysis - Newser
Palvella Therapeutics Inc. stock trend forecastSwing Gain Strategy with Entry Forecast - Newser
Key External Factors That Drive Palvella Therapeutics Inc. Stock Price MovementsFree Daily Chart Pattern Stock Forecast - Newser
Does Palvella Therapeutics Inc. fit your quant trading modelStock Market Trend and Pattern Analysis - Newser
Exit strategy if you’re trapped in Palvella Therapeutics Inc.Free Step-by-Step Stock Investment Guide - Newser
Real time scanner hits for Palvella Therapeutics Inc. explainedProfitable Trading Blueprint with Entry Zones - Newser
Palvella Therapeutics Inc. stock volume spike explainedShort Term Profit Strategy with Entry Cues - Newser
Palvella Therapeutics Q2 2025 Earnings Call Scheduled for August 14 | PVLA Stock News - Stock Titan
Analysts Set Expectations for PVLA Q2 Earnings - Defense World
How to read the order book for Palvella Therapeutics Inc.AI Trade Signal Forecast with Chart Logic - Newser
What makes Palvella Therapeutics Inc. stock price move sharplyHigh Yield Signals with Entry Timing - Newser
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Palvella Therapeutics (NASDAQ:PVLA) Rating Increased to Strong-Buy at Lifesci Capital - Defense World
Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
Raymond James Initiates Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $54 - 富途牛牛
Raymond James initiates Palvella Therapeutics stock with Outperform rating By Investing.com - Investing.com Canada
Lifesci Capital Initiates Coverage on Palvella Therapeutics (NASDAQ:PVLA) - Defense World
Lifesci Capital Upgrades Palvella Therapeutics (NASDAQ:PVLA) to “Strong-Buy” - Defense World
Palvella Therapeutics CEO to Share Rare Disease Pipeline Updates at Major Growth Conference - Stock Titan
Lifesci Capital Begins Coverage on Palvella Therapeutics (NASDAQ:PVLA) - Defense World
Palvella Therapeutics (NASDAQ:PVLA) Stock Rating Upgraded by Lifesci Capital - Defense World
Palvella Therapeutics Inc Azioni (PVLA) Dati Finanziari
Non sono disponibili dati finanziari per Palvella Therapeutics Inc (PVLA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):